INHIBITORS OF CYCLIC-AMP RESPONSE ELEMENT-BINDING PROTEIN

摘要

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and/or the CREB-CBP pathway, (e.g., proliferative diseases, for example, cancer (e.g., lung cancer or breast cancer), and inflammatory disease (e.g., pancreatic fibrosis or liver fibrosis)). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.